Matrix metalloproteinase-2 contributes to increased platelet reactivity in patients with metastatic prostate cancer: a preliminary study.
Jurasz
Paul
P
Department of Medical Oncology, Cross Cancer Institute and Department of Oncology, University of Alberta, Edmonton, AB, Canada T6G 2H7. Paul.K.Jurasz@uth.tmc.edu
North
Scott
S
Venner
Peter
P
Radomski
Marek W
MW
D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D001792:Blood Platelets / Q000378:metabolism*; D006801:Humans; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000097:blood* / Q000378:metabolism; D008875:Middle Aged; D009362:Neoplasm Metastasis; D015539:Platelet Activation; D011471:Prostatic Neoplasms / Q000097:blood* / Q000201:enzymology*; D018570:Risk Assessment / Q000379:methods*
D014408:Biomarkers, Tumor; D020778:Matrix Metalloproteinase 2